Imatinib for relapsed BCR/ABL positive leukemias.
Ottmann
O G
OG
J.W. Goethe-University, Medical Hospital III, Dept., Hematology/Oncology, Theodor-Stern-Kai 7, 60596 Frankfurt, Germany.
Wassmann
B
B
Hoelzer
D
D
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001549:Benzamides; D019008:Drug Resistance, Neoplasm; D016044:Fusion Proteins, bcr-abl / Q000032:analysis*; D006801:Humans; D000068877:Imatinib Mesylate; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics / Q000628:therapy*; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use*; D012074:Remission Induction; D033581:Stem Cell Transplantation
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl